The present Competitive Intelligence Report about BlyS, BAFF & APRIL Targeted Therapy provides a competitor evaluation in the field of molecules targeting B-lymphocyte stimulator (BlyS), B-cell activating factor of the TNF family (BAFF) and of a proliferation-inducing ligand (APRIL) as of February 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of antibodies and antibody-based molecules targeting B-lymphocyte stimulator (BlyS), B-cell activating factor of the TNF family (BAFF) and of a proliferation-inducing ligand (APRIL) for treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis. In addition, the report lists company-specific R&D pipelines of PSMA & PSA targeted therapeutics. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
- BlyS, BAFF & APRIL Targeted Therapy
- Corporate BlyS, BAFF & APRIL R&D Pipelines
- About La Merie
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.